Tag: stock options

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

PROGRAMME DE RACHAT

SCOTTSDALE, Ariz., June 27, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé”), a plant-based energy beverage company, and Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT”, “Safety Shot”, or the “Company”), a wellness and dietary supplement company, are pleased to announce the successful completion of the previously announced business combination pursuant to which Safety Shot has acquired all of the issued and outstanding commons shares of Yerbae (the “Yerbae Shares”) pursuant to a court-approved plan of arrangement (the “Transaction”).

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing  

DELTA, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- WestBond Enterprises Corporation (TSX-V: WBE) has posted a loss of $52,380 for the year ended March 31, 2025 ($210,683 loss for the year ended March 31, 2024). The value ascribed to stock options granted during the year contributed to this small loss. Sales increased 4.9% to $9,673,002 this year compared to $9,219,948 for the year ended March 31, 2024.